Japanese Patent Grant
CRISM Therapeutics Corporation has been granted patent number 7800909 by the Japanese Patent Office for its lead product, ChemoSeed, specifically relating to biodegradable chemotherapeutic drug implants containing irinotecan and their use in treating brain tumours like glioblastoma. This patent covers manufacturing processes and therapeutic applications, strengthening the company's intellectual property position in a key market and enhancing its appeal to potential commercial partners. CRISM Therapeutics is preparing for its registration-grade Phase 2 clinical trial of irinotecan-ChemoSeed in glioblastoma patients, scheduled to commence in Q1 2026.
Select text to share a quote on X · sign in to keep highlights & notes in your CRTX notes
CRISM Therapeutics Corporation (AIM: CRTX), a UK clinical-stage drug delivery company focused on the localised and sustained delivery of chemotherapy drugs, announces that it has been granted a patent (7800909) by the Japanese Patent Office.
The patent relates to the Company's lead product, ChemoSeed®, for chemotherapeutic drug implants and more, particularly, to biodegradable chemotherapeutic drug implants comprising irinotecan. ChemoSeed was invented by Professor Chris McConville, CRISM's Chief Scientific Officer.
The patent covers the manufacturing processes for the preparation of these chemotherapeutic drug implants and to their use in therapy, in particular in treating brain tumours such as glioblastoma.
Commenting on the patent grant, CRISM Therapeutics' CEO, Andrew Webb, said: "We are pleased to have started 2026 by strengthening our IP position through the grant of this patent in Japan, which we view as a key market. This latest patent grant broadens our appeal to potential commercial partners. We remain confident in CRISM's prospects for the year ahead as we prepare for our registration-grade Phase 2 clinical trial of irinotecan-ChemoSeed in glioblastoma."
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.